吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌系统评价  

Systematic Review of Gefitinib Combined with Kanglaite Injection in Treatment of Advanced Non-small Cell Lung Cancer

作　　者：马超[1] 崔学军[1] 张铭[2] 

机构地区：[1]上海中医药大学附属龙华医院,上海200032 [2]上海交通大学附属胸科医院,上海200030

出　　处：《辽宁中医药大学学报》2013年第4期73-76,共4页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：上海高校选拔培养优秀青年教师科研专项基金项目[上海市教委(szy10061)]

摘　　要：目的:系统评价吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌的有效率、生活质量和毒副反应。方法:计算机检索Cochrane Library、Pubmed、EMBASE、中国科技期刊全文数据库、中国生物医学文献数据库、万方数据库、中国期刊全文数据库,检索年限从各数据库建库至2012年7月。另外,使用Google Scholar等搜索引擎在互联网上查找相关文献。纳入吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌的随机对照试验(RCTs)。2名评价者独立评价纳入研究的质量并提取资料,并用RevMan5.0软件进行统计分析。结果:共纳入2篇RCTs,Meta分析结果显示,吉非替尼联合康莱特组与单用吉非替尼组相比,在有效率[RR=1.29,95%CI(0.84,1.91),P=0.21]和肝功能损伤[RR=0.91,95%CI(0.39,2.41),P=0.83]方面没有统计学差异,吉非替尼联合康莱特组治疗晚期非小细胞肺癌有利于改善生活质量[RR=0.21,95%CI(0.08,0.58),P=0.003]。结论:吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌可以改善患者生活质量,但在提高有效率和减少肝功能损伤方面,与单用吉非替尼相比,未见明显优势。Objective ： To systematically evaluate the efficiency, quality of life and adverse reaction in the treatment of advanced non-small cell lung cancer with gefitinib combined with Kanglaite Injection. Methods ： We searched the Cochrane Library, Pubmed, EMBASE, Chinese Science and Technology Journal Full-text Database, Chinese Biomedical Literature Database, Wanfang Database, and China Journal Full- text Database, with retrieval time from the foundation of database to July 2012. In addition, we searched for related literatures in Google Scholar search engine, incorporating randomized control trials（RCTs） in the treatment of advanced non-small cell lung cancer with gefitinib combined with Kanglaite Injection. Two reviewers independently evaluated the quality of included studies and extracted data, and statistical analysis was performed through RevMan5.0 software. Results ： Two RCTs were totally incorporated. The result of Meta-analysis showed that there was no statistical difference between gefitinib combined with Kanglaite Injection group and single gefitinib group in effective rate[RR=l.29, 95%CI （0.84, 1.91）, P=0.21]and liver function damage[RR=0.91, 95%CI （0.39, 2.41）, P=0.83],while gefitinib combined with Kanglaite Injection group was conducive to improve the quality of life in treatment of advanced non-small cell hmg cancer[RR=0.21, 95%CI （0.08, 0.58）, P=0.003]. Conclusion： Gefitinib combined with Kanglaite Injection group can improve the quality of life of patients in the treatment of advanced non-small ceil lung cancer, but has no obvious advantages in improving effective rate and reducing the damage of liver function compared with the single gefitinib group.

关 键 词：吉非替尼 康莱特注射液 晚期非小细胞肺癌 系统评价 META分析 

分 类 号：R734.2[医药卫生—肿瘤]